期刊
NEW ENGLAND JOURNAL OF MEDICINE
卷 365, 期 26, 页码 2463-2472出版社
MASSACHUSETTS MEDICAL SOC
DOI: 10.1056/NEJMoa1111288
关键词
-
资金
- Sanofi
- Bayer Healthcare
- Boehringer Ingelheim
- Bristol-Myers Squibb
- Daiichi Sankyo
- Eisai
- GlaxoSmithKline
- Pfizer
- EKOS
- Medscape
- Merck
- Portola
- Johnson Johnson
- AstraZeneca
- Association des Pharmaciens de l'Industrie-Communication Globale Sante-Prioritis
- Bayer
- Lilly
- Agence Nationale de Recherche contre le SIDA
BACKGROUND Although thromboprophylaxis reduces the incidence of venous thromboembolism in acutely ill medical patients, an associated reduction in the rate of death from any cause has not been shown. METHODS We conducted a double-blind, placebo-controlled, randomized trial to assess the effect of subcutaneous enoxaparin (40 mg daily) as compared with placebo - both administered for 10 +/- 4 days in patients who were wearing elastic stockings with graduated compression - on the rate of death from any cause among hospitalized, acutely ill medical patients at participating sites in China, India, Korea, Malaysia, Mexico, the Philippines, and Tunisia. Inclusion criteria were an age of at least 40 years and hospitalization for acute decompensated heart failure, severe systemic infection with at least one risk factor for venous thromboembolism, or active cancer. The primary efficacy outcome was the rate of death from any cause at 30 days after randomization. The primary safety outcome was the rate of major bleeding during and up to 48 hours after the treatment period. RESULTS A total of 8307 patients were randomly assigned to receive enoxaparin plus elastic stockings with graduated compression (4171 patients) or placebo plus elastic stockings with graduated compression (4136 patients) and were included in the intention-to-treat population. The rate of death from any cause at day 30 was 4.9% in the enoxaparin group as compared with 4.8% in the placebo group (risk ratio, 1.0; 95% confidence interval [CI], 0.8 to 1.2; P=0.83). The rate of major bleeding was 0.4% in the enoxaparin group and 0.3% in the placebo group (risk ratio, 1.4; 95% CI, 0.7 to 3.1; P=0.35). CONCLUSIONS The use of enoxaparin plus elastic stockings with graduated compression, as compared with elastic stockings with graduated compression alone, was not associated with a reduction in the rate of death from any cause among hospitalized, acutely ill medical patients. (Funded by Sanofi; LIFENOX ClinicalTrials.gov number, NCT00622648.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据